Vimarsana
Biggest News Aggregation in the World

Page 7 - Mayo Score News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mayo Score. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mayo Score Today - Breaking & Trending Today

Gossamer Bio Announces GB004 Topline Results from Phase 2 SHIFT-UC Study in Ulcerative Colitis and Provides Corporate Update - Vimarsana News

Gossamer Bio Announces GB004 Topline Results from Phase 2 SHIFT-UC Study in Ulcerative Colitis and Provides Corporate Update

25.04.2022 - Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced topline ... Seite 1

DGAP-News: Abivax reports excellent one-year efficacy and safety data of ABX464 phase 2b maintenance trial in ulcerative colitis - Vimarsana News

DGAP-News: Abivax reports excellent one-year efficacy and safety data of ABX464 phase 2b maintenance trial in ulcerative colitis

DGAP-News: ABIVAX / Key word(s): Study results Abivax reports excellent one-year efficacy and safety data of ABX464 phase 2b maintena...

FDA Approves Upadacitinib for Ulcerative Colitis - Vimarsana News

FDA Approves Upadacitinib for Ulcerative Colitis

Upadacitinib has been shown to rapidly control symptoms in adults with moderate to severe active ulcerative colitis. It’s the first FDA approval for the JAK inhibitor in gastroenterology.

Rinvoq Approved for Moderately to Severely Active Ulcerative Colitis - Vimarsana News

Rinvoq Approved for Moderately to Severely Active Ulcerative Colitis

The FDA has approved Rinvoq (upadacitinib) for adults with moderately to severely active ulcerative colitis.

Source: empr.com
Rinvoq Approved for Moderately to Severely Active Ulcerative Colitis - Vimarsana News

Rinvoq Approved for Moderately to Severely Active Ulcerative Colitis

The FDA has approved Rinvoq (upadacitinib) for adults with moderately to severely active ulcerative colitis.